Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12723099 | 0.91 | KDM4E (0.60) | NAMPTKDM4EPKMABCB1ACKR3 | |
| SCHEMBL3272146 | 0.91 | KDM4E (0.60) | NAMPTKDM4EPKMABCB1ACKR3 | |
| SCHEMBL19706814 | 0.91 | KDM4E (0.60) | NAMPTKDM4EPKMABCB1ACKR3 | |
| SCHEMBL31617924 | 0.91 | NAMPT (0.56) | NAMPTKDM4EPKMSYKMAPT | |
| SCHEMBL12722658 | 0.89 | ACKR3 (0.61) | NAMPTKDM4EPKMACKR3HTR6 | |
| SCHEMBL1622524 | 0.89 | ACKR3 (0.61) | NAMPTKDM4EPKMACKR3HTR6 | |
| SCHEMBL12722612 | 0.89 | ACKR3 (0.61) | NAMPTKDM4EPKMACKR3HTR6 | |
| SCHEMBL24392263 | 0.89 | NAMPT (0.51) | NAMPTKDM4EPKMABCB1SYK | |
| SCHEMBL1241067 | 0.89 | KDM4E (0.69) | KDM4EPKMCYP2D6CYP3A4NPC1 | |
| SCHEMBL3274653 | 0.88 | NAMPT (0.47) | NAMPTKDM4EPKMABCB1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2226322-B1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8927588-B2 | Imidazole carbonyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-01-06 | — | — | US | disclosed |
| US-20140073622-A1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-03-13 | — | — | US | disclosed |
| US-8536197-B2 | Imidazole carbonyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-17 | — | — | US | disclosed |
| CN-102143746-A | CDK modulators | EXELIXIS INC | 2011-08-03 | — | — | CN | disclosed |
| CN-101959882-A | Imidazole carbonyl compound | DAIICHI SANKYO CO LTD | 2011-01-26 | — | — | CN | disclosed |
| EP-1781669-B1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-10-13 | — | — | EP | disclosed |
| EP-1781669-B1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-10-13 | — | — | EP | disclosed |
| EP-2226322-A1 | IMIDAZOLE CARBONYL COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-7655648-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-02-02 | — | — | US | disclosed |
| US-7655648-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-02-02 | — | — | US | disclosed |
| US-7655648-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-02-02 | — | — | US | disclosed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| US-20070244091-A1 | Antibacterial Agents | GLAXO GROUP LIMITED, A CORPORATION | 2007-10-18 | — | — | US | disclosed |
| US-20070244091-A1 | Antibacterial Agents | GLAXO GROUP LIMITED, A CORPORATION | 2007-10-18 | — | — | US | disclosed |
| US-20070244091-A1 | Antibacterial Agents | GLAXO GROUP LIMITED, A CORPORATION | 2007-10-18 | — | — | US | disclosed |
| EP-1781669-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006017468-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244091-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | NAMPT 164/4885KDM4E 4436/4885PKM 3911/4885 |
| US-20140073622-A1 | IMIDAZOLE CARBONYL COMPOUND | TOP1, TOP2B, TOP2A | NAMPT 1750/4885KDM4E 211/4885PKM 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.